Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Pipeline
Cancer Program
Fibrosis Program
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements and Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Recent Posts
Approval from Korean regulator to initiate Phase 2 accent pancreatic cancer trial in Korea
Approval from Korean regulator to initiate Phase 2 accent pancreatic cancer trial in Korea
AUSBIZ | Interview with Dr Chris Burns
Phase 1B of ACCENT Trial in Pancreatic Cancer Complete
VIDEO | The Market Herald
Archives
December 2023
November 2023
October 2023
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 2022
April 2022
Categories
Company News
Media
Uncategorized
Videos
December 4th, 2023
Approval from Korean regulator to initiate Phase 2 accent pancreatic cancer trial in Korea
Read More
December 4th, 2023
Approval from Korean regulator to initiate Phase 2 accent pancreatic cancer trial in Korea
Read More
November 21st, 2023
AUSBIZ | Interview with Dr Chris Burns
Read More
October 30th, 2023
Phase 1B of ACCENT Trial in Pancreatic Cancer Complete
Read More
October 20th, 2023
VIDEO | The Market Herald
Read More
October 9th, 2023
AACR Ovarian Cancer Conference Presentation
Read More
September 29th, 2023
Poster presentation at AACR Special Conference on Pancreatic Cancer
Read More
September 25th, 2023
Amplia appoints new CFO
Read More
August 2nd, 2023
ACCENT Trial Recruitment Update
Read More
July 31st, 2023
Quarterly Activities and Cash Flow Report - 30 June 2023
Read More
July 20th, 2023
Investor Newsletter July 2023
Read More
July 19th, 2023
Dr Chris Burns to speak at Bio Connections Australia
Read More
June 21st, 2023
International Nonproprietary Name announced for AMP945
Read More
June 13th, 2023
Independent Non-Executive Director recognised in King’s Birthday Honours List
Read More
May 29th, 2023
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
Read More
May 22nd, 2023
PROACTIVE INTERVIEW | Dr Chris Burns discusses Amplia's collaboration with CSIRO
Read More
May 22nd, 2023
Amplia receives grant to collaborate with CSIRO
Read More
May 9th, 2023
Enrolment of Cohort 3 of ACCENT Trial in Pancreatic Cancer Complete
Read More
April 26th, 2023
Quarterly Activities and Cash Flow Report - 31 March 2023
Read More
April 19th, 2023
First Patient Recruited to Cohort 3 of ACCENT Trial in Pancreatic Cancer
Read More
1
2
3
4
5
